Pharmacology of botulinum toxin type B

European Journal of Neurology

Volumn 8, Issue SUPPL. 4, 2001, Pages 9-12

  Setler, P E ^a  

^a ELAN PHARMACEUTICALS   (United States)

Author keywords

Botulinum toxin type b; Cervical dystonia

Indexed keywords

EID: 3242802406     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1331.2001.00003.x     Document Type: Article

References (4)

1. Arezzo JC, Litwak MS, Caputo FA, Shopp GM, Meyer KM (2000). A comparison of the spread of biological activity of NeuroBloc™ (botulinum toxin type B) and Botox (botulinum toxin type A) in a monkey model. Mov Disord 15(Suppl. 3):159.
2. Brin MF, Lew MF, Adler CH et al. (1999). Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 53:1431-1438.
3. Callaway J, Patel N, Chung J, Dias B. (1999). Biochemical characterization of NeuroBloc™ (botulinum toxin type B). Program and abstract book for the International Conference 1999: Basic and therapeutic aspects of botulinum and tetanus toxins. Orlando, Florida, USA, November 16-18 1999: 27.
4. Hirtzer P, Chung J, Dias R et al. (2000). Complex integrity of botulinum toxin type B (NeuroBloc™): implications for the incidence of secondary non-responders. Eur J Neural 7(Suppl. 3): 113.